JACOBO FUTRAN

Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology YONKERS, NY NPI 1508975640

General Payments — all program years on this page

$9,411.94

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 179
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $652.59 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $652.5919

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $326.494
Amgen Inc. $209.337
UCB, Inc. $29.672
NOVARTIS PHARMACEUTICALS CORPORATION $28.382
Aurinia Pharma U.S., Inc. $18.791
Acerta Pharma LLC $14.381
E.R. Squibb & Sons, L.L.C. $13.171
Organon LLC $12.381

By program year

Program yearAmountRecords
2018 $4,965.4841
2019 $2,363.829
2020 $83.694
2021 $227.8020
2022 $666.2842
2023 $452.2844
2024 $652.5919

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086849229 Novartis Pharmaceuticals Corporation $15.14 07/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086849231 Novartis Pharmaceuticals Corporation $13.24 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101711359 E.R. Squibb & Sons, L.L.C. $13.17 10/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103762126 ABBVIE INC. $148.24 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103762128 ABBVIE INC. $7.95 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103762130 ABBVIE INC. $20.30 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103762132 ABBVIE INC. $150.00 10/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105287069 AstraZeneca Pharmaceuticals LP $14.38 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111578933 Amgen Inc. $9.31 01/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111578935 Amgen Inc. $10.25 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111578937 Amgen Inc. $10.65 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111578939 Amgen Inc. $12.34 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111578941 Amgen Inc. $146.59 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117255921 Amgen Inc. $10.67 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117255923 Amgen Inc. $9.52 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136311731 Organon Llc $12.38 05/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143027918 UCB, Inc. $13.61 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143027920 UCB, Inc. $16.06 11/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150680429 Aurinia Pharma U.S., Inc. $18.79 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.